Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II, Double-Blind, Randomized Trial Of AVOVA-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens) Vs. Autologous Peripheral Blood Mononuclear Cells (MC) In Patients With Stage III Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma After Primary Therapy

Trial Profile

Phase II, Double-Blind, Randomized Trial Of AVOVA-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens) Vs. Autologous Peripheral Blood Mononuclear Cells (MC) In Patients With Stage III Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma After Primary Therapy

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ovapuldencel-T (Primary) ; Granulocyte macrophage colony stimulating factor
  • Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms AVOVA-1
  • Sponsors AiVita Biomedical; Caladrius Biosciences; NeoStem Oncology
  • Most Recent Events

    • 01 Mar 2019 According to an AiVita Biomedical media release, thus far in the trial, 11 appropriate patient tumor samples have been received, with all 11 having successfully been expanded into viable cell lines for use in the creation of the Company's autologous vaccine. Additional clinical sites are being initiated.
    • 01 Mar 2019 According to an AiVita Biomedical media release, trial design and methodologies will be presented by Dr. Robert O. Dillman at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium 2019.
    • 21 Feb 2019 According to an AiVita Biomedical media release, as of now, eight subjects have been randomized to receive the study therapy, which is administered in a series of eight injections along with standard care.Eleven subjects are currently enrolled in the study across five clinical sites, with three additional sites opening soon.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top